Weiss Valuation: Where Does ABBV Stand Today?
At 3.18%, ABBV's current yield is near the bottom of its 10-year historical range (3.04%–6.64%). By the Weiss method this indicates that the market is pricing the stock for optimism — investors are paying a premium relative to the income the stock generates. The historical median yield is 4.32%, suggesting the stock is trading well above fair value.
The undervalued price threshold — the level at which ABBV historically becomes an attractive buy — currently sits at $101.50. The overvalued threshold, above which the stock is historically expensive, is $222.05. The current price of $211.93 places the stock above the overvalued band — a signal to review position sizing.
Dividend Quality Assessment
AbbVie Inc. scores 37/100 on DividendVisual's quality scale — a Below Average rating. Investors should carefully review dividend sustainability before acting on the Weiss signal. Key metrics: the dividend consumes 59% of free cash flow, growing at 6.8% annually over the past 5 years.
AbbVie Inc. has maintained its dividend without a cut for 9 years, establishing a meaningful income track record.
10-Year Yield History
Over the past decade, AbbVie Inc.'s dividend yield has ranged from a low of 3.04% (when the stock was most expensive relative to its dividend) to a high of 6.64% (when it was most attractively priced). The historical median yield — a reasonable proxy for fair value — is 4.32%.
Investors who consistently bought ABBV near its historical yield maximum and held for 3–5 years have, historically, earned both above-average income and above-average capital appreciation as the yield mean-reverted toward the median. This is the core logic of yield-based valuation: price and yield are inversely related, so buying high yield means buying low price.
Income Projection: What ABBV Could Generate
A $10,000 investment at the current price and yield would generate approximately $318 in year-one income. With dividends reinvested and a 6.8% annual growth rate maintained, that same investment would produce roughly $967 per year in income by year 10 — a yield on cost of 9.7%.
These projections assume no share price appreciation — only the compounding effect of reinvested dividends at a constant price. In practice, share price changes will affect the total return. The projection is intended to illustrate the power of dividend reinvestment over time, not to predict a specific outcome.
Key Risks to Consider
Investors should be aware of the following factors: an overall quality score below 50, warranting additional due diligence on dividend sustainability. These do not necessarily signal an imminent dividend cut, but they reduce the margin of safety relative to higher-scoring peers.
Beyond company-specific factors, all dividend stocks carry interest rate risk: when rates rise, income investors have alternatives, and dividend stock valuations tend to compress. AbbVie Inc.'s position in the Healthcare sectorshould be evaluated in the context of your portfolio's overall rate sensitivity.
Bottom Line
At current prices, AbbVie Inc. is trading at historically elevated valuations relative to its dividend yield. Income investors may find better entry points elsewhere in the dividend universe. Existing holders have no urgent reason to sell — the dividend remains intact — but initiating a new position here means accepting below-median long-term income returns relative to cost.